Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis

Theoretical Biology and Medical Modelling

Volumn 10, Issue 1, 2013, Pages

  Wang, Jun ^a   Zhang, Le ^a,b   Jing, Chenyang ^a   Ye, Gang ^c   Wu, Hulin ^b   Miao, Hongyu ^b   Wu, Yukun ^d   Zhou, Xiaobo ^e  

^a SOUTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Agent based model; Anti angiogenesis; Drug synergism; Melanoma; Microenvironment; Multi scale

Indexed keywords

APOPTOSIS; HUMAN; MELANOMA; PATHOLOGY; SKIN TUMOR; THEORETICAL MODEL; VASCULARIZATION; ARTICLE;

APOPTOSIS; HUMANS; MELANOMA; MODELS, THEORETICAL; SKIN NEOPLASMS;

EID: 84879088712     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-10-41     Document Type: Article

References (41)

1. Early detection and treatment of skin cancer. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ, Am Fam Physician 2000 62 357 368 375-356, 381-352 10929700
2. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, British Journal of Dermatology 2010 163 238 256 10.1111/j.1365-2133.2010.09883.x 20608932
3. Apoptosis and melanoma chemoresistance. Soengas MS, Lowe SW, Oncogene 2003 22 3138 3151 10.1038/sj.onc.1206454 12789290
4. Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method. Ziemys A, Kojic M, Milosevic M, Kojic N, Hussain F, Ferrari M, Grattoni A, J Comput Phys 2011 230 5722 5731 10.1016/j.jcp.2011.03.054
5. A 3-D model of ligand transport in a deforming extracellular space. Kojić N, Huang A, Chung E, Ivanović M, Filipović N, Kojić M, Tschumperlin DJ, Biophys J 2010 99 3517 3525 10.1016/j.bpj.2010.09.044 21112275
6. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Decuzzi P, Ferrari M, Biomaterials 2007 28 2915 2922 10.1016/j.biomaterials.2007.02.013 17363051
7. The hallmarks of cancer. Hanahan D, Weinberg RA, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
8. A history of the study of solid tumor growth: the contribution of mathematical modeling. Araujo RP, McElwain DL, Bull Math Biol 2004 66 1039 1091 10.1016/j.bulm.2003.11.002 15294418
9. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Ribba B, Colin T, Schnell S, Theor Biol Med Model 2006 3 7 10.1186/1742-4682-3-7 16472396
10. Continuous and discrete mathematical models of tumor-induced angiogenesis. Anderson AR, Chaplain MA, Bull Math Biol 1998 60 857 899 10.1006/bulm.1998.0042 9739618
11. Growth of nonnecrotic tumors in the presence and absence of inhibitors. Byrne HM, Chaplain MA, Math Biosci 1995 130 151 181 10.1016/0025-5564(94)00117-3 8527869
12. Mathematical modeling of tumor-induced angiogenesis. Chaplain MA, McDougall SR, Anderson AR, Annu Rev Biomed Eng 2006 8 233 257 10.1146/annurev.bioeng.8.061505.095807 16834556
13. Nonlinear simulation of tumor growth. Cristini V, Lowengrub J, Nie Q, J Math Biol 2003 46 191 224 10.1007/s00285-002-0174-6 12728333
14. Compartment modeling. Holz M, Fahr A, Adv Drug Deliv Rev 2001 48 249 264 10.1016/S0169-409X(01)00118-1 11369085
15. Morphologic instability and cancer invasion. Cristini V, Frieboes HB, Gatenby R, Caserta S, Ferrari M, Sinek J, Clin Cancer Res 2005 11 6772 6779 10.1158/1078-0432.CCR-05-0852 16203763
16. A mathematical model for cisplatin cellular pharmacodynamics. El-Kareh AW, Secomb TW, Neoplasia 2003 5 161 169 New York, NY 12659689
17. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V, Cancer Res 2009 69 4484 4492 10.1158/0008-5472.CAN-08-3740 19366802
18. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. Sinek JP, Sanga S, Zheng X, Frieboes HB, Ferrari M, Cristini V, J Math Biol 2009 58 485 510 10.1007/s00285-008-0214-y 18781304
19. Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Zheng X, Wise SM, Cristini V, Bull Math Biol 2005 67 211 259 10.1016/j.bulm.2004.08.001 15710180
20. Multi-scale, multi-resolution brain cancer modeling. Zhang L, Chen LL, Deisboeck TS, Math Comput Simul 2009 79 2021 2035 10.1016/j.matcom.2008.09.007 20161556
21. Multiscale agent-based cancer modeling. Zhang L, Wang ZH, Sagotsky JA, Deisboeck TS, J Math Biol 2009 58 545 559 10.1007/s00285-008-0211-1 18787828
22. Development of a three-dimensional multiscale agent-based tumor model: Simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. Zhang L, Athale CA, Deisboeck TS, J Theor Biol 2007 244 96 107 10.1016/j.jtbi.2006.06.034 16949103
23. Continuous and discrete mathematical models of tumor-induced angiogenesis. Anderson ARA, Chaplain MAJ, Bull Math Biol 1998 60 857 899 10.1006/bulm.1998.0042 9739618
24. Simulating brain tumor heterogeneity with a multiscale agent-based model: Linking molecular signatures, phenotypes and expansion rate. Zhang L, Strouthos CG, Wang Z, Deisboeck TS, Math Comput Model 2009 49 307 319 10.1016/j.mcm.2008.05.011 20047002
25. A new approach for the treatment of Malignant Melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Mansour AM, Joachim D, Norbert E, Hamada FM, Badary OA, Clemens U, Iduna F, Kratz2 F, Cancer Res 2003 63 4062 12874007
26. Sunitinib: from rational design to clinical efficacy. Chow LQM, Eckhardt SG, J Am Soc Clin Oncol 2007 25 884 896 10.1200/JCO.2006.06.3602
27. Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. Zhang L, Athale CA, Deisboeck TS, J Theor Biol 2007 244 96 107 10.1016/j.jtbi.2006.06.034 16949103
28. Inhibition of melanoma tumor growth in vivo by survivin targeting. Douglas G, Kim PJ, Schechner JS, Altieri DC, PNAS 2001 98 635 640 10.1073/pnas.98.2.635 11149963
29. Diffusion coefficients of oxygen, hydrogen peroxide and glucose in a hydrogel. van Stroe-Biezen SAM, Everaerts FM, Janssen LJJ, Tacken RA, Anal Chim Acta 1993 273 553 560 10.1016/0003-2670(93)80202-V
30. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Chronopoulos A, Trudeau K, Roy S, Huang H, Vinores SA, Roy S, Curr Eye Res 2011 36 747 753 10.3109/02713683.2011.585735 21780924
31. Núñez AD, Experimental estimate of the diffusivity of Vascular Endothelial Growth Factor. Thesis (S.B.), Massachusetts Institute of Technology, Massachusetts Institute of Technology Dept of Mechanical Engineering 2006 http://hdl.handle.net/1721.1/36721
32. Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis. Sun X, Zhang L, Tan H, Bao J, Strouthos C, Zhou X, BMC Bioinforma 2012 13 218 10.1186/1471-2105-13-218
33. Drug inhibition profile prediction for NFkB pathway in multiple myeloma. Peng H, Wen J, Li H, Chang J, Zhou X, PLoS One 2011 6 14750 10.1371/journal. pone.0014750 21408099
34. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. Sinek JP, Sanga S, Zheng X, Frieboes HB, Ferrari M, Cristini V, J Math Biol 2009 58 485 510 10.1007/s00285-008-0214-y 18781304
35. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DSL, Chinnaiyan AM, Markovitz DM, Soengas MS, Cancer Res 2009 69 6405 6413 10.1158/0008-5472.CAN-09-1063 19679545
36. Tumor angiogenesis and polyamines: α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in Ovo and the proliferation of vascular endothelial cells in vitro. Takigawa M, Enomoto M, Nishida Y, Pan H-O, Kinoshita A, Suzuki F, Cancer Res 1990 50 4131 4138 1693880
37. Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway. Sun X, Su J, Bao J, Peng T, Zhang L, Zhang Y, Yang Y, Zhou X, Biomaterials 2012 33 8265 8276 10.1016/j.biomaterials.2012.07.041 22910219
38. Systems biology and combination therapy in the quest for clinical efficacy. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK, Nat Chem Biol 2006 2 458 466 10.1038/nchembio817 16921358
39. Design and analysis of drug combination experiments. Straetemans R, O'Brien T, Wouters L, Van Dun J, Janicot M, Bijnens L, Burzykowski T, Aerts M, Biom J 2005 47 299 308 10.1002/bimj.200410124 16053254
40. Significance testing of the spearman rank correlation coefficient. Zar JH, J Am Stat Assoc 1972 67 578 580 10.1080/01621459.1972.10481251
41. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Anderson ARA, Weaver AM, Cummings PT, Quaranta V, Cell 2006 127 905 915 10.1016/j.cell.2006.09.042 17129778